Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02426918 · ClinicalTrials.gov registry record · Phase 2
Study of Debio 1450 for Bacterial Skin Infections
A Phase 2 study, sponsored by Debiopharm International.
- Completed
- Registry status
- Phase 2
- Development phase
- 330
- Enrollment target
NCT02426918 is a Phase 2 study that has completed, run by Debiopharm International. The registered enrollment target is 330 participants.
The verdict
NCT02426918, a Phase 2 study, has completed, sponsored by Debiopharm International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 330 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of 2 different doses of intravenous and oral Debio 1450 compared with intravenous vancomycin and oral linezolid in the treatment of patients with staphylococcal ABSSSI.
Interventions
- DRUG Linezolid
- DRUG Debio 1450 IV
- DRUG Debio 1450 Oral
- DRUG Debio 1450 Oral Placebo
- DRUG Linezolid Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02426918
The ClinicalTrials.gov registry entry for NCT02426918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Linezolid is the first listed.
NCT02426918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02426918 about?
NCT02426918 is a clinical study titled "Study of Debio 1450 for Bacterial Skin Infections". The primary objective of this study is to evaluate the efficacy of 2 different doses of intravenous and oral Debio 1450 compared with intravenous vancomycin and oral linezolid in the treatment of patients with staphylococcal ABSSSI.
What is the current status of trial NCT02426918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 330 participants. The study started on 2015-05. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02426918?
The interventions under investigation include: Linezolid (DRUG), Debio 1450 IV (DRUG), Debio 1450 Oral (DRUG), Debio 1450 Oral Placebo (DRUG), Linezolid Placebo (DRUG).
Who is sponsoring clinical trial NCT02426918?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.